Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study) - Archive ouverte HAL Access content directly
Journal Articles Hepatology Year : 2017

Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)

Laurent Alric
  • Function : Author
  • PersonId : 881462
Aurelie Pailhe
  • Function : Author
Severine Gibowski
  • Function : Author

Abstract

67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) - Boston, MA - 2016-11-11
Not file

Dates and versions

hal-01487921 , version 1 (13-03-2017)

Identifiers

  • HAL Id : hal-01487921 , version 1

Cite

Victor De Ledinghen, Claire Laforest, Christophe Hézode, Stanislas Pol, Alain Renault, et al.. Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study). Hepatology, 2017, 64 (6), pp.1130A--1130A. ⟨hal-01487921⟩
205 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More